(Baltimore, MD) - Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative solutions for complex brain surgeries, proudly announces the issuance of a groundbreaking patent for its novel prosthetic translucent, cranial implant. The ClearFit® implant integrates brain-computer interface (BCI), brain mapping, and neurosonography (brain ultrasound). This product sets a new standard in neurosurgical procedures, marking the first time a single implant has been patented to cover three critical areas. ClearFit’s patented technology was recently on the cover of Science Translational Medicine demonstrating promising research around this implant and neurosonography.*
Longeviti received patent issue notification from the United States Patent and Trademark Office (USPTO) for US Patent No. 12,004,954 B2 entitled “Method for performing single-stage cranioplasty reconstruction with a clear custom craniofacial implant.” It was approved in June 2024.
“This technology and exclusive IP surrounding the ClearFit prosthetic implant family, represents a significant advancement in the field of neurosurgery. It allows Longeviti to openly collaborate with others in the field across the globe,” said Jesse Christopher, CEO, Longeviti Neuro Solutions. “Together, Longeviti and its partners will advance neurosonography and neurosurgical patient care to significantly reduce the cost and time it takes to monitor brains anywhere in the world, real-time.”
The implant's integration of BCI technology allows for direct communication between the brain and external devices, offering control and interaction for patients. Coupled with advanced brain mapping capabilities, the implant provides surgeons with real-time, detailed anatomical images, allowing for new real-time tools to enhance precision during surgical procedures. In addition, the incorporation of neurosonography within the cranial implant allows for continuous, non-invasive monitoring of brain activity and conditions, vastly improving postoperative care and monitoring.
Click here to read more.